A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus
收藏DataCite Commons2025-11-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011700/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is used.
提供机构：
Vivli
创建时间：
2025-08-14
